| Literature DB >> 35433699 |
Debasis Sahu1,2, Subasa Chandra Bishwal3, Md Zubbair Malik4, Sukanya Sahu3, Sandeep Rai Kaushik3, Shikha Sharma5, Ekta Saini6, Rakesh Arya3, Archana Rastogi7, Sandeep Sharma8, Shanta Sen1, R K Brojen Singh4, Chuan-Ju Liu2, Ranjan Kumar Nanda3, Amulya Kumar Panda1.
Abstract
Troxerutin (TXR) is a phytochemical reported to possess anti-inflammatory and hepatoprotective effects. In this study, we aimed to exploit the antiarthritic properties of TXR using an adjuvant-induced arthritic (AIA) rat model. AIA-induced rats showed the highest arthritis score at the disease onset and by oral administration of TXR (50, 100, and 200 mg/kg body weight), reduced to basal level in a dose-dependent manner. Isobaric tags for relative and absolute quantitative (iTRAQ) proteomics tool were employed to identify deregulated joint homogenate proteins in AIA and TXR-treated rats to decipher the probable mechanism of TXR action in arthritis. iTRAQ analysis identified a set of 434 proteins with 65 deregulated proteins (log2 case/control≥1.5) in AIA. Expressions of a set of important proteins (AAT, T-kininogen, vimentin, desmin, and nucleophosmin) that could classify AIA from the healthy ones were validated using Western blot analysis. The Western blot data corroborated proteomics findings. In silico protein-protein interaction study of tissue-proteome revealed that complement component 9 (C9), the major building blocks of the membrane attack complex (MAC) responsible for sterile inflammation, get perturbed in AIA. Our dosimetry study suggests that a TXR dose of 200 mg/kg body weight for 15 days is sufficient to bring the arthritis score to basal levels in AIA rats. We have shown the importance of TXR as an antiarthritic agent in the AIA model and after additional investigation, its arthritic ameliorating properties could be exploited for clinical usability.Entities:
Keywords: adjuvant induced arthritis; anti-inflammatory; antioxidant; iTRAQ; proteomics; troxerutin
Year: 2022 PMID: 35433699 PMCID: PMC9009527 DOI: 10.3389/fcell.2022.845457
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Schematic representation of the experimental approach used in this study. (A) Nitric oxide inhibition assay simultaneously with the cytotoxicity of TXR was evaluated using RAW264.7 cells. (B) Induction of adjuvant-induced arthritis (AIA) and the treatment plan. (C) Joint homogenates from multiple study groups were used for proteomics experiments. (D) Informatics analyses were used for identifying the key regulator proteins.
FIGURE 2TXR has limited cytotoxicity in RAW 264.7 cell lines and anti-arthritic potential in AIA rats. The released nitrite concentration in the cell supernatant (A) and viability (B) of the RAW 264.7 cells with or without TXR. (C) Blood plasma nitrite content in the experimental animals using Griess nitrite assay. (D) Representative pictures of the ventral aspect of footpads. (E) Radiograph of the tibiotarsal joints. Arrows indicate the osteophyte formation, and the oval structure mark the extent of osteolysis. (F) Representative histological micrograph of the hematoxylin and eosin-stained slides of rat joints. (Original magnification ×10) (js: joint space; c: cartilage; b: bone; p: pannus; s: synovium; mls: multilayered synovial membrane; fj: fused joints; and m: matrix). The arrowheads indicate the damage in the synovial lining and the oval structures show neutrophils in the epiphyseal cartilage. (G) AIA score at day 21. (H) The cumulative radiographic score. (I) Histological score. AIA: adjuvant-induced arthritis; DS: diclofenac sodium-treated AIA; TXR 50, 100, and 200 mg/kg dose of troxerutin.
FIGURE 3TXR treatment suppresses arthritis scores in adjuvant-induced arthritis rats in a dose-dependent manner. The arthritis score (mean ± SD) (A), change in footpad thickness and (B) change in the body weight, (C) show a trend with TXR administration. Photomicrographs of hematoxylin and eosin-stained histological slides of the kidney (D) and liver (E) of rats of different study groups. The histological scores of kidneys (F) and liver (G) were derived from the analysis of different parameters. n.s.: not significant at 95% confidence and p-value of less than 0.05 was considered as significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
FIGURE 4Global proteomics assay of tissue joint homogenate proteins (n = 434) in the experimental study groups. (A) The scatter plots showing all the identified proteins and their fold change values in the experimental groups. All the identified joint proteins were categorized according to cellular components (B), molecular functions (C), and biological processes (D). (E) Heatmap of important deregulated proteins that classified the study groups correctly. The color and its intensity explain the fold change values. (F) The iTRAQ ratios of the important deregulated proteins as observed in different study groups. (G) Western blot analysis of important marker molecules (alpha-1-antitrypsin, desmin, nucleophosmin, T-kininogen, and vimentin) and their relative integrated densitometric values (IDV) of Western blot bands (H). The IDV of AIA was 100% constant against the other experimental samples.
FIGURE 5A system level organization of protein networks in arthritis models. (A) The figure shows all the networks comprising all 434 proteins; this is the first level of the protein network. (B) The plots of LCP-correlation is a function of CN for each module/submodule (plots correspond to each module/sub-module of the network) of C9 path. This also contains the plots of PH and PLCP as a function of the level of organization. (C) Organization of sub-modules and modules at different levels as indicated by concentric circles while the arrows indicate sub-modules built from previous modules leading to the identification of key regulators of the arthritis network. (D) The modular path of the key regulator proteins from complete network to motif with the structures of modules/submodules at different stages of community finding. This leads to finding out three sub-modules through which the first four leading hubs passed through. These leading hubs comprise of the 15 in silico key regulators and the probability distribution of the latter is a function of the degree of organization.
FIGURE 6Mechanism of action study of TXR (A) Protein–protein interaction (PPI) of all 15 key regulator proteins computationally derived through the community finding method. (B) String interaction network of the 15 in silico key regulator proteins. The PPI networks were constructed using STRING 10.0 with a medium confidence level (0.4) and all available prediction methods. (C) Venn diagram showing C9 as the common protein in all the lists of proteins, viz., list 1 = 15 proteins (in silico key regulators), list 2 = 11 proteins (≥1.5 fold expressed proteins in AIA when compared with the TXR group), and list 3 = 27 proteins (significantly differentially expressed (p ≤ 0.05) proteins between AIA and TXR). (D) Probable step of TXR action on C9-based membrane attack complex formation and its role in inflammation and arthritis. (E) Molecular docking of C9 protein with TXR. Expanded region of the docking site shows the interacting amino acids of C9 protein with the TXR molecule in the Ligplot.